Rocheusa ( Rocheusa )


Rocheusa's picture

About Rocheusa

Roche AG is a Swiss multinational health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange.

Rocheusa press release, blog etc

11/13/2018 - 13:43 FDA grants priority review to Roches Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
11/01/2018 - 16:09 Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
11/01/2018 - 02:52 Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
11/01/2018 - 02:02 Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
10/29/2018 - 11:05 New STAIRWAY study data shows potential for extended durability with Roches faricimab in neovascular age-related macular degeneration (nAMD)
10/24/2018 - 15:32 Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
10/21/2018 - 21:02 Roches Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
10/21/2018 - 20:41 Roches Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
10/20/2018 - 22:05 Roches investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
10/19/2018 - 22:42 Roches Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
10/17/2018 - 04:43 Roche reports very strong growth in the first nine months of 2018
10/15/2018 - 04:02 Roches Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
10/15/2018 - 03:57 Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
10/08/2018 - 19:22 Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress
10/03/2018 - 21:34 FDA approves Roches Hemlibra for haemophilia A without factor VIII inhibitors
10/03/2018 - 18:47 Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
10/02/2018 - 21:02 Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
10/02/2018 - 13:26 Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS